IGF-1 DES

Truncated IGF-1 variant (Des(1-3)) - missing the first three amino acids, which prevents IGF-binding-protein binding. Very short half-life (20–30 min) and local IM use for site enhancement; not the systemic LR3 frame.

Research chemicalWADA S2 prohibitedLocal IMSite-specific

Key facts

Common routesIM (local)

Half-life20–30 minutes

Typical range20–50 mcg per site

Résumé

IGF-1 DES (Des(1-3)IGF-1) is a truncated variant of human IGF-1 missing the first three amino acids at the N-terminus. The modification prevents binding to IGF-binding proteins (IGFBPs) - nearly 100% of the peptide circulates "free" and is potently available at receptors. But the half-life is very short (20–30 min), which makes systemic use unattractive.

Instead the standard use is local intramuscular injection directly into the trained target muscle pre-workout, to maximise receptor saturation before the peptide degrades. That's the "site enhancement" frame: targeting individual muscle groups that lag in bodybuilding terms. Unlike IGF-1 LR3 (systemic, long-acting), DES sits in a narrow local niche.

Notes sur le mécanisme

IGF-1 receptor activation

Binds IGF-1 receptors with high affinity, stimulates protein synthesis and inhibits proteolysis. Drives muscle hypertrophy and potentially hyperplasia (splitting of muscle cells).

IGFBP avoidance

Doesn't bind IGF-binding proteins. That makes the injected peptide instantly available at receptors at the injection site - a massive, acute activity spike rather than the slow release native IGF-1 shows.

Localised effect

Unlike IGF-1 LR3, which acts systemically, DES stays largely local to the injection site. That reduces systemic side effects but requires multiple injections for multiple target muscles and makes use more dose- and timing-sensitive.

Dosing patterns

Site enhancement (bodybuilding standard)

20–50 mcg per site, 15–30 min pre-workout, bilateral IM into the target muscle. Total dose 40–100 mcg per session. The injection has to be timed close to training because otherwise the peptide is degraded before the training-induced receptor sensitivity peaks.

Pre-injection carbs

DES can lower blood glucose like insulin. 30–50 g fast carbs before the injection, then the workout. Hypoglycaemia is real even though dampened by the local action - the small systemic component is enough.

Cycling discipline

Short cycles (typically 4 weeks) are standard because of receptor desensitisation at the high local potency. Don't run year-round. The growth-factor class risk frame from IGF-1 LR3 applies - see cross-references.

Aperçu des données

Tier: Limited data. Mechanism well-characterised in animal models from Tomas et al. 1991 and Ballard et al. 1996. Human clinical trials specific to DES don't exist. Bodybuilding community use is real but the signal is anecdotal-grade.

Animal models

Tomas 1991, Ballard 1996: higher potency than rhIGF-1 in rat models, with IGFBP avoidance as the key mechanism. Local IM use in animal studies shows focal hypertrophy effects.

Human data

No published clinical trials specific to DES. Risk and efficacy are extrapolated from IGF-1 receptor pharmacology and bodybuilding community logs.

Considérations de sécurité

Very short half-life lowers systemic load relative to LR3, but local IM injection brings its own risks: injection-site trauma, tendon / vessel proximity in certain target muscles, acute hypoglycaemia if carbs are skipped. Cumulative growth-pathway exposure is lower per dose, but doses are more frequent.

Common cautions

Acute hypoglycaemia if pre-injection carbs are skipped
IM trauma at the target muscle - know the site anatomy before injecting
Receptor desensitisation on extended cycling - 4-week cycles standard
Theoretical tumour-promotion risk in pre-existing malignancies - growth-factor class